Endpoint western blot analyses of tumor xenografts harvested from animals that were treated with or without Ruxolitinib confirmed the inhibition of STAT signaling in the treated and slower growing mixed tumors (Fig. 4r). The gene discussed is SOAT1; the disease is neoplasm.